Please login to the form below

Not currently logged in
Email:
Password:

TDF

This page shows the latest TDF news and features for those working in and with pharma, biotech and healthcare.

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

laboratory parameters compared to F/TDF (emtricitabine/tenofovir disproxil fumarate). ... TDF - in HIV-1 positive treatment-naïve adult patients.

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to its predecessor Viread (tenofovir disoproxil fumarate, TDF) but at only 10% of the dosage. ... With less tenofovir in the bloodstream, TAF

  • Gilead gets EU nod for TAF-based triple therapy for HIV Gilead gets EU nod for TAF-based triple therapy for HIV

    It is a follow up to Gilead's $1.4bn Complera, which contains emtricitabine, rilpivirine and tenofovir disoproxil fumarate (TDF) and is among the most prescribed HIV drugs. ... TAF is a new salt form of TDF that is ten-fold more potent and can be

  • Gilead bags EU approval for next-generation HIV drug Gilead bags EU approval for next-generation HIV drug

    Clinical trials have shown that TAF is safer than TDF in terms of renal toxicity and bone demineralisation, to recognised toxicities associated with the original drug. ... Gilead is in the process of replacing all its TDF-based HIV drugs with TAF

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    The FDA's approval was based on phase III trials of the tenofovir alafenamide (TAF) based regimen showing non-inferiority to a tenofovir disoproxil fumarate (TDF) regimen and improvement in bone

  • Gilead wins US approval for second TAF-based HIV drug Gilead wins US approval for second TAF-based HIV drug

    The new drug is a follow-up to Gilead's Complera - which contains emtricitabine, Janssen's rilpivirine and tenofovir disoproxil fumarate (TDF) - but replaces the latter with a new salt of ... Gilead is in the process of replacing its TDF-based HIV

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics